Torrent Pharma focuses on diabetes
India's Torrent Pharmaceuticals, which just last month announced the setting up of a new division focusing on diabetes products (Marketletter February 27), has now stressed the importance of this business, saying that it currently holds 2% of the Indian oral hypoglycemic drug market, valued at 7.8 billion rupees ($175.5 million), said the firm's vice president of marketing, Sujesh Vasudevan, in a recent interview.
Three products in pipeline
He added that, with the company's diabetes product AzuCa (which is the Spanish word for sugar), "we hope to increase our market share to 15%-20%. Of the seven research projects currently in our pipeline, three are focused on diabetes."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze